Mesenchymal stem cell therapy for cirrhosis: Present and future perspectives

Young Woo Eom, Gaeun Kim, Soonkoo Baik

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Cirrhosis occurs as a result of various chronic liver injuries, which may be caused by viral infections, alcohol abuse and the administration of drugs and chemicals. Recently, bone marrow cells (BMCs), hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) have been used for developing treatments for cirrhosis. Clinical trials have investigated the therapeutic potential of BMCs, HSCs and MSCs for the treatment of cirrhosis based on their potential to differentiate into hepatocytes. Although the therapeutic mechanisms of BMC, HSC and MSC treatments are still not fully characterized, the evidence thus far has indicated that the potential therapeutic mechanisms of MSCs are clearer than those of BMCs or HSCs with respect to liver regenerative medicine. MSCs suppress inflammatory responses, reduce hepatocyte apoptosis, increase hepatocyte regeneration, reverse liver fibrosis and enhance liver functionality. This paper summarizes the clinical studies that have used BMCs, HSCs and MSCs in patients with liver failure or cirrhosis. We also present the potential therapeutic mechanisms of BMCs, HSCs and MSCs for the improvement of liver function.

Original languageEnglish
Pages (from-to)10253-10261
Number of pages9
JournalWorld Journal of Gastroenterology
Volume21
Issue number36
DOIs
Publication statusPublished - 2015 Sep 28

Fingerprint

Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Hematopoietic Stem Cells
Bone Marrow Cells
Fibrosis
Hepatocytes
Liver
Liver Cirrhosis
Therapeutics
Regenerative Medicine
Liver Failure
Virus Diseases
Alcoholism
Regeneration
Clinical Trials
Apoptosis
Wounds and Injuries
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

@article{1d6331a7e1f74359991b245b1680e339,
title = "Mesenchymal stem cell therapy for cirrhosis: Present and future perspectives",
abstract = "Cirrhosis occurs as a result of various chronic liver injuries, which may be caused by viral infections, alcohol abuse and the administration of drugs and chemicals. Recently, bone marrow cells (BMCs), hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) have been used for developing treatments for cirrhosis. Clinical trials have investigated the therapeutic potential of BMCs, HSCs and MSCs for the treatment of cirrhosis based on their potential to differentiate into hepatocytes. Although the therapeutic mechanisms of BMC, HSC and MSC treatments are still not fully characterized, the evidence thus far has indicated that the potential therapeutic mechanisms of MSCs are clearer than those of BMCs or HSCs with respect to liver regenerative medicine. MSCs suppress inflammatory responses, reduce hepatocyte apoptosis, increase hepatocyte regeneration, reverse liver fibrosis and enhance liver functionality. This paper summarizes the clinical studies that have used BMCs, HSCs and MSCs in patients with liver failure or cirrhosis. We also present the potential therapeutic mechanisms of BMCs, HSCs and MSCs for the improvement of liver function.",
author = "Eom, {Young Woo} and Gaeun Kim and Soonkoo Baik",
year = "2015",
month = "9",
day = "28",
doi = "10.3748/wjg.v21.i36.10253",
language = "English",
volume = "21",
pages = "10253--10261",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "36",

}

Mesenchymal stem cell therapy for cirrhosis : Present and future perspectives. / Eom, Young Woo; Kim, Gaeun; Baik, Soonkoo.

In: World Journal of Gastroenterology, Vol. 21, No. 36, 28.09.2015, p. 10253-10261.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mesenchymal stem cell therapy for cirrhosis

T2 - Present and future perspectives

AU - Eom, Young Woo

AU - Kim, Gaeun

AU - Baik, Soonkoo

PY - 2015/9/28

Y1 - 2015/9/28

N2 - Cirrhosis occurs as a result of various chronic liver injuries, which may be caused by viral infections, alcohol abuse and the administration of drugs and chemicals. Recently, bone marrow cells (BMCs), hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) have been used for developing treatments for cirrhosis. Clinical trials have investigated the therapeutic potential of BMCs, HSCs and MSCs for the treatment of cirrhosis based on their potential to differentiate into hepatocytes. Although the therapeutic mechanisms of BMC, HSC and MSC treatments are still not fully characterized, the evidence thus far has indicated that the potential therapeutic mechanisms of MSCs are clearer than those of BMCs or HSCs with respect to liver regenerative medicine. MSCs suppress inflammatory responses, reduce hepatocyte apoptosis, increase hepatocyte regeneration, reverse liver fibrosis and enhance liver functionality. This paper summarizes the clinical studies that have used BMCs, HSCs and MSCs in patients with liver failure or cirrhosis. We also present the potential therapeutic mechanisms of BMCs, HSCs and MSCs for the improvement of liver function.

AB - Cirrhosis occurs as a result of various chronic liver injuries, which may be caused by viral infections, alcohol abuse and the administration of drugs and chemicals. Recently, bone marrow cells (BMCs), hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) have been used for developing treatments for cirrhosis. Clinical trials have investigated the therapeutic potential of BMCs, HSCs and MSCs for the treatment of cirrhosis based on their potential to differentiate into hepatocytes. Although the therapeutic mechanisms of BMC, HSC and MSC treatments are still not fully characterized, the evidence thus far has indicated that the potential therapeutic mechanisms of MSCs are clearer than those of BMCs or HSCs with respect to liver regenerative medicine. MSCs suppress inflammatory responses, reduce hepatocyte apoptosis, increase hepatocyte regeneration, reverse liver fibrosis and enhance liver functionality. This paper summarizes the clinical studies that have used BMCs, HSCs and MSCs in patients with liver failure or cirrhosis. We also present the potential therapeutic mechanisms of BMCs, HSCs and MSCs for the improvement of liver function.

UR - http://www.scopus.com/inward/record.url?scp=84942333053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942333053&partnerID=8YFLogxK

U2 - 10.3748/wjg.v21.i36.10253

DO - 10.3748/wjg.v21.i36.10253

M3 - Article

C2 - 26420953

AN - SCOPUS:84942333053

VL - 21

SP - 10253

EP - 10261

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 36

ER -